Leerink Partners initiated coverage of Oric Pharmaceuticals with an Outperform rating. The analyst report did not include a price target. The rating was disclosed via Benzinga.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
